These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1761081)

  • 1. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease.
    Durif F; Jeanneau E; Serre-Debeauvais F; Deffond D; Eschalier A; Tournilhac M
    Eur J Clin Pharmacol; 1991; 41(5):493-4. PubMed ID: 1761081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease.
    Durif F; Paire M; Deffond D; Eschalier A; Dordain G; Tournilhac M; Lavarenne J
    Clin Neuropharmacol; 1993 Apr; 16(2):157-66. PubMed ID: 8477411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of sublingual apomorphine in Parkinson's disease.
    Durif F; Deffond D; Tournilhac M
    J Neurol Neurosurg Psychiatry; 1990 Dec; 53(12):1105. PubMed ID: 2292708
    [No Abstract]   [Full Text] [Related]  

  • 5. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
    Deffond D; Durif F; Tournilhac M
    J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):101-3. PubMed ID: 8429309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

  • 8. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
    Montastruc JL; Rascol O; Senard JM; Gualano V; Bagheri H; Houin G; Lees A; Rascol A
    Clin Neuropharmacol; 1991 Oct; 14(5):432-7. PubMed ID: 1742752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.
    Hughes AJ; Webster R; Bovingdon M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1991 Dec; 14(6):556-61. PubMed ID: 1773424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of apomorphine by various routes in parkinsonism.
    Gancher ST; Nutt JG; Woodward WR
    Mov Disord; 1991; 6(3):212-6. PubMed ID: 1922125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual apomorphine and Parkinson's disease.
    Lees AJ; Montastruc JL; Turjanski N; Rascol O; Kleedorfer B; Peyro Saint-Paul H; Stern GM; Rascol A
    J Neurol Neurosurg Psychiatry; 1989 Dec; 52(12):1440. PubMed ID: 2614447
    [No Abstract]   [Full Text] [Related]  

  • 14. Sublingual apomorphine solution in Parkinson's disease.
    Panegyres PK; Graham SJ; Williams BK; Higgins BM; Morris JG
    Med J Aust; 1991 Sep; 155(6):371-4. PubMed ID: 1921784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
    Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
    Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
    Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
    Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
    Thijssen E; Tuk B; Cakici M; van Velze V; Klaassen E; Merkus F; van Laar T; Kremer P; Groeneveld GJ
    Clin Transl Sci; 2024 May; 17(5):e13796. PubMed ID: 38712716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia.
    Harder S; Baas H; Demisch L; Simon E
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):355-62. PubMed ID: 9707348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.